YOLFTbeta
08

CrystalGenomics Inc

083790 · KQ · Healthcare / Pharmaceuticals

754.00KRW-10.00 (-1.31%)

Price History

Full chart

Market Stats

Previous Close764.00
Open796.00
Day Range733.00 – 796.00
52-Week Range711.00 – 1,667.00
Volume116.81K
Market Cap71.67B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.02
50-Day Avg898.18
200-Day Avg1,154.08

About

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEODr. Joong-Myung Cho Ph.D.
  • Employees65
  • HeadquartersTower A, Korea Bio Park, Seongnam-si, South Korea, 463-400, Korea
  • Websitehttps://www.cgxinc.com

Leadership

  • Willim SchmditExec. Officer
  • Hui-Sung LeeExec. Officer
  • Jong-Ryu ChoiExec. Officer · b. 1959
  • Doh-Young LeeExec. Officer
  • Dr. Joong-Myung Cho Ph.D.Chairman, Founder, CEO & Pres · b. 1948
  • Dr. Seonggu Ro Ph.D.Co-Founder, Chief Technology Officer, Exec. VP and Director · b. 1960
  • Dr. In Chul ChungVP & CFO
  • Mr. Sang-Cheon AhnExec. Managing Director and Director · b. 1963
  • Dr. Yong-Rae HongExec. MD & Research Head of Institute for Drug Discovery · b. 1968
  • Cheol-Soon LeeExec. Officer

Financials

Income Statement

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue3.81B3.72B4.80B4.54B6.14B14.52B12.18B13.89B14.01B30.22B42.38B4.32B4.88B7.25B27.39B
Growth (%)--2.28%+28.96%-5.43%+35.29%+136.72%-16.18%+14.06%+0.86%+115.78%+40.21%-89.80%+12.90%+48.67%+277.64%
Cost of Revenue---1.32B316.35M4.86B3.33B2.90B9.20B17.31B20.67B3.07B3.42B7.77B29.33B
Gross Profit---3.22B5.82B9.67B8.84B10.99B4.81B12.91B21.71B1.26B1.46B-519.05M-1.94B
Gross Margin---71.01%94.84%66.56%72.62%79.10%34.31%42.72%51.23%29.05%29.86%-7.16%-7.09%
Operating Expense---10.45B9.81B13.76B15.55B9.96B21.63B4.99B45.99B25.68B17.44B54.45B24.16B
Operating Income----7.23B-3.99B-4.09B-6.71B1.03B-16.82B7.92B-24.29B-24.42B-15.98B-54.97B-26.10B
Operating Margin----159.37%-65.05%-28.14%-55.13%7.40%-120.09%26.20%-57.31%-565.15%-327.56%-757.86%-95.28%
EBITDA------------18.20B-45.86B-42.33B-9.56B
EBITDA Margin------------421.06%-939.98%-583.66%-34.89%
Net Income----11.93B-4.85B-2.18B-8.58B6.91B-37.59B-9.84B-15.90B-23.87B-48.92B-51.54B-3.52B
Net Income Margin----263.05%-79.04%-15.00%-70.43%49.74%-268.34%-32.55%-37.52%-552.35%-1002.81%-710.63%-12.85%
R&D8.67B7.03B6.66B6.56B6.10B7.07B7.54B3.43B-4.98B4.86B6.34B7.18B11.32B4.42B
R&D as % of Total Revenue227.70%189.01%138.82%144.59%99.45%48.65%61.92%24.73%-16.48%11.47%146.81%147.22%156.05%16.15%
Interest Expense0000000005.74B2.43B2.28B2.09B3.48B4.27B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%19.00%5.75%52.74%42.93%47.94%15.58%

Balance Sheet

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets62.96B54.56B88.77B106.05B127.28B128.67B119.47B256.92B379.19B316.96B332.93B322.61B243.12B260.47B224.11B
Total Liabilities32.59B32.29B52.61B51.02B55.34B45.51B27.88B72.45B230.14B102.20B125.09B134.34B97.82B161.95B105.43B
Total Equity30.37B22.27B36.16B55.03B71.94B83.16B91.59B184.47B149.05B214.76B207.84B188.28B145.29B98.52B105.15B
Cash16.58B16.90B6.54B27.83B14.66B13.41B13.38B28.28B22.67B47.22B458.00K29.96B23.01B6.93M11.58B
Total Debt----33.53B15.38B13.00B32.29B54.45B52.44B-----
Net Debt---------14.47B43.13B39.78B8.69B10.17B32.51B

Cash Flow

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow----3.75B-4.73B-8.30B1.63B-1.21B-7.14B-16.38B-11.46B-24.40B-32.41B-25.85B-17.41B
Investing Cash Flow-5.15B-593.82M-2.86B-1.18B-17.18B-123.79B23.71B-33.92B-5.65B4.85B21.93B41.48B-
Financing Cash Flow35.40B1.86B32.20B24.44B4.49B7.52B13.44B137.98B460.99M45.68B802.07M18.55B2.93B4.30B-
Capital Expenditure2.28B39.37M760.00M150.79M440.77M704.25M10.74B293.43M618.27M6.75B10.61B14.68B23.56B9.94B7.99B
Free Cash Flow----------25.34B-22.12B-39.08B-55.97B-35.79B-25.41B
Dividends Paid------1.30B1.30B1.30B1.30B---2.52B-
FCF to OCF---------154.66%193.05%160.15%172.70%138.46%145.90%
Dividend Paid to FCF----------5.13%----7.04%-

Earnings

Report DateJun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Mar 14, 2015May 14, 2015Aug 18, 2015Nov 2, 2015Feb 25, 2016May 16, 2016Aug 16, 2016Nov 14, 2016May 15, 2017Aug 11, 2017Nov 14, 2017Mar 9, 2018May 15, 2018Aug 13, 2018Nov 14, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020May 17, 2021Aug 17, 2021Nov 15, 2021Feb 25, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Feb 28, 2023May 15, 2023Aug 17, 2023Nov 14, 2023May 14, 2024Aug 13, 2024Nov 12, 2024Feb 27, 2025May 12, 2025Aug 11, 2025Nov 10, 2025Feb 27, 2026Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------------------------------------------------------
EPS Actual3.4379.17-16.17-11.91-58.07-2.14-50.56-56.26-68.39-80.11-92.32-53.01-88.03-71.93-124.25-72.33-109.03-78.60-55.93-91.25-46.86-61.97-90.39-38.88-45.35-7.46-20.3628.75-6.41-4.27-33.11-42.038.45-94.08-28.7952.82-30.6718.99-81.15-104.38-523.08-103.45-31.30238.0013.453.00-11.32-240.40-40.93-89.21-58.79-160.62-63.24-473.00278.53-98.13-186.21-128.83-291.35-62.28-134.00-158.79309.01-58.16-86.59
Surprise-----------------------------------------------------------------
Timing----------------------After-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-market----------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-market--

Key Statistics & Ratios

Market Cap71.67B
Enterprise Value110.25B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.46
Price / Book0.79
Revenue (TTM)45.02B
Gross Profit (TTM)21.71B
EBITDA-16.41B
Profit Margin-64.56%
Operating Margin-43.29%
Return on Equity-4221.29%
Return on Assets-3.79%
Shares Outstanding40.45M
Shares Float51.09M
Beta0.02
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 1, 20213:2
  • Jul 10, 201813:10
  • May 15, 2018971:954
  • Apr 29, 201113:10
  • Mar 10, 201112351:11549
  • Dec 2, 201013:10
  • Nov 26, 200713:10
  • Oct 18, 2007885:836